Vertex, CRISPR Therapeutics Amend Collaboration Agreement
20 April 2021 - 10:40PM
Dow Jones News
By Michael Dabaie
Vertex Pharmaceuticals Inc. and CRISPR Therapeutics amended
their collaboration agreement for CTX001 in sickle cell disease and
beta thalassemia.
CTX001 is an investigational gene editing therapy being
developed as a potentially curative therapy for sickle cell disease
and transfusion-dependent beta-thalassemia.
CRISPR Therapeutics shares were up 7% to $123.05 premarket.
Under the terms of the amended agreement, Vertex will lead
global development, manufacturing and commercialization of CTX001
with support from CRISPR Therapeutics. Vertex will be responsible
for 60% of program costs and will receive 60% of profits from
future sales of CTX001 worldwide, representing a 10% increase in
program economics compared to the previous agreement.
CRISPR will be responsible for 40% of costs and will receive 40%
of profits. Additionally, CRISPR will receive a $900 million
upfront payment, with potential for a $200 million payment upon the
first regulatory approval of CTX001.
Write to Michael Dabaie at michael.dabaie@wsj.com
(END) Dow Jones Newswires
April 20, 2021 08:25 ET (12:25 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
Vertex Pharmaceuticals (NASDAQ:VRTX)
Historical Stock Chart
From Apr 2024 to May 2024
Vertex Pharmaceuticals (NASDAQ:VRTX)
Historical Stock Chart
From May 2023 to May 2024